InvestorsHub Logo
Followers 35
Posts 182
Boards Moderated 0
Alias Born 05/03/2020

Re: mjbaker84 post# 124569

Tuesday, 10/20/2020 12:10:01 AM

Tuesday, October 20, 2020 12:10:01 AM

Post# of 232555
That's only $24. With potential approval of Leromlimab in all sequelae, the global peak sales will be closed to $5b peak sales! Gilead is forecasting $1b to $3b for Remde for that for Moderate CV19 only. Very limited use.

Btw, as for my model, that's per qtr here in the U.S. $600m with 25% qtrly compounded growth rate usage or in sales.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News